Current knowledge and open issues regarding Bevacizumab in gynaecological neoplasms

Critical Reviews in Oncology/Hematology

Volumn 83, Issue 1, 2012, Pages 35-46

  Bellati, Filippo ^a,b   Napoletano, Chiara ^b   Gasparri, Maria Luisa ^a   Ruscito, Ilary ^a   Marchetti, Claudia ^a   Pignata, Sandro ^c   Tomao, Federica ^a   Benedetti Panici, Pierluigi ^a   Nuti, Marianna ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c National Cancer Institute   (Italy)

Author keywords

Angiogenesis; Bevacizumab; Cervical cancer; Chemotherapy; Gynaecological cancer; Ovarian cancer; Target therapy; VEGF

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PACLITAXEL; PLACEBO; PLATINUM COMPLEX; SORAFENIB; TAXANE DERIVATIVE; TOPOTECAN; VASCULOTROPIN;

ADVANCED CANCER; ADVERSE OUTCOME; ANEMIA; ANOREXIA; ARTERY THROMBOSIS; BLEEDING DISORDER; BLOOD TOXICITY; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL EFFECTIVENESS; COLON CANCER; COLON CARCINOMA; COLORECTAL CANCER; DEEP VEIN THROMBOSIS; DIARRHEA; DIGESTIVE SYSTEM FISTULA; DIGESTIVE SYSTEM PERFORATION; DISSEMINATED INTRAVASCULAR CLOTTING; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; ENTEROCUTANEOUS FISTULA; EVIDENCE BASED MEDICINE; FATIGUE; GASTROINTESTINAL HEMORRHAGE; GLIOBLASTOMA; GYNECOLOGIC CANCER; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; INFECTION; INTESTINAL DYSMOTILITY; ISCHEMIA; KIDNEY CANCER; KIDNEY METASTASIS; LEUKOPENIA; LIVER DISEASE; LOW DRUG DOSE; LUNG CANCER; METABOLIC DISORDER; METASTASIS; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NEUTROPENIA; OVARY CANCER; OVARY CARCINOMA; PAIN; PERITONEUM CANCER; PRIMARY TUMOR; PROTEIN EXPRESSION; PROTEINURIA; PULMONARY HYPERTENSION; RECTUM CARCINOMA; RECURRENT CANCER; REVIEW; SKIN MANIFESTATION; SOLID TUMOR; TREATMENT DURATION; URETER FISTULA; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; UTERINE TUBE CARCINOMA; UTERINE TUBE TUMOR; UTERUS SARCOMA; VASCULAR DISEASE; VEIN THROMBOSIS; WOUND HEALING IMPAIRMENT;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84862127138     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2011.09.006     Document Type: Review

References (101)

1. Presta L.G., Chen H., O'Connor S.J., et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997, 57:4593-4599.
2. Matulonis U.A., Berlin S., Ivy P., et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol 2009, 27:5601-5606.
3. Moore M., Hirte H.W., Siu L., et al. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 2005, 16:1688-1694.
4. Friedlander M., Hancock K.C., Rischin D., et al. A phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol 2010, 119:32-37.
5. Coleman R.L., Kamat A., Iyer R. Phase I and pharmacokinetic study of the novel VEGF-directed fusion protein, afl ibercept, in combination with docetaxel in women with recurrent ovarian, fallopian tube, and primary peritoneal cancer. J Clin Oncol ASCO Ann Meet Proc (Post-Meet Ed) 2009, 27(15S May 20 Suppl.):5549. [Abstract].
6. Bodnar L., Górnas M., Szczylik C. Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: a phase II study. Gynecol Oncol 2011, [Epub ahead of print].
7. Biagi J.J., Oza A.M., Chalchal H.I., et al. A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study. Ann Oncol 2011, 22:335-340.
8. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285:1182-1186.
9. Folkman J., Watson K., Ingber D., Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989, 339:58-61.
10. Gullino P.M. Angiogenesis and neoplasia. N Engl J Med 1981, 305:884-885.
11. Paley P.J., Staskus K.A., Gebhard K., et al. Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 1997, 80:98-106.
12. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86:353-364.
13. Aubry K., Barriere G., Chable-Rabinovitch H., et al. Molecular mechanisms regulating the angiogenic phenotype in tumors: clinical impact in the future. Anticancer Res 2007, 27:3111-3119.
14. Maxwell P.H., Dachs G.U., Gleadle J.M., et al. Hypoxia inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 1997, 94:8104-8109.
15. Dameron K.M., Volpert O.V., Tainsky M.A., Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994, 265:1582-1584.
16. Iozzo R.V. Tumor stroma as a regulator of neoplastic behavior. Agonistic and antagonistic elements embedded in the same connective tissue. Lab Invest 1995, 73:157-160.
17. Senger D.R., Galli S.J., Dvorak A.M., Perruzzi C.A., Harvey V.S., Dvorak H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983, 219:983-985.
18. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat Med 2003, 9:669-676.
19. Kassim S.K., El-Salahy E.M., Fayed S.T., et al. Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients. Clin Biochem 2004, 37:363-369.
20. Cooper B.C., Ritchie J.M., Broghammer C.L., et al. Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clin Cancer Res 2002, 8:3193-3197.
21. Li L., Wang L., Zhang W., et al. Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer. Anticancer Res 2004, 24:1973-1979.
22. Hefler L.A., Zeillinger R., Grimm C., et al. Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. Gynecol Oncol 2006, 103:512-517.
23. Kuemmel S., Thomas A., Landt S., et al. Circulating vascular endothelial growth factors and their soluble receptors in pre-invasive, invasive and recurrent cervical cancer. Anticancer Res 2009, 29:641-645.
24. Randall L.M., Monk B.J., Darcy K.M., et al. Markers of angiogenesis in high-risk, early-stage cervical cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2009, 112:583-589.
25. Cheng W.F., Chen C.A., Lee C.N., Chen T.M., Hsieh F.J., Hsieh C.Y. Vascular endothelial growth factor in cervical carcinoma. Obstet Gynecol 1999, 93:761-765.
26. Loncaster J.A., Cooper R.A., Logue J.P., Davidson S.E., Hunter R.D., West C.M. Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix. Br J Cancer 2000, 83:620-625.
27. Cheng W.F., Chen C.A., Lee C.N., Wei L.H., Hsieh F.J., Hsieh C.Y. Vascular endothelial growth factor and prognosis of cervical carcinoma. Obstet Gynecol 2000, 96:721-726.
28. Holland C.M., Day K., Evans A., Smith S.K. Expression of the VEGF and angiopoietin genes in endometrial atypical hyperplasia and endometrial cancer. Br J Cancer 2003, 89:891-898.
29. Jain R.K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001, 7:987-989.
30. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
31. Miller K., Wang M., Gralow J., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357:2666-2676.
32. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluoruracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
33. Reck M., von Pawel J., Zatloukal P., et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009, 27:1227-1234.
34. (June 2006). http://www.fda.gov/.
35. Giantonio B.J., Catalano P.J., Meropol N.J., et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007, 25:1539-1544.
36. (November 2006). http://www.fda.gov/.
37. Sandler A., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl Med 2006, 355:2542-2550.
38. (October 2008). http://www.fda.gov/.
39. (May 2009). http://www.fda.gov/.
40. (February 2008). http://www.fda.gov/.
41. Lee J.B., Woo O.H., Park K.H. Bevacizumab for salvage treatment of metastatic breast cancer: a systemic review and meta-analysis of randomized controlled trials. Invest New Drugs 2009.
42. (April 2011). http://www.fda.gov/.
43. Heintz A.P., Odicino F., Maisonneuve P., et al. Carcinoma of the ovary. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006, 95(Suppl. 1):S161-S192.
44. Pectasides D., Pectasides E., Papaxoinis G., et al. Primary fallopian tube carcinoma: results of a retrospective analysis of 64 patients. Gynecol Oncol 2009, 115:97-101.
45. Kindelberger D.W., Lee Y., Miron A., et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol 2007, 31:161-169.
46. Chen C.A., Cheng W.F., Lee C.N., et al. Serum vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with patient survival. Gynecol Oncol 1999, 74:235-240.
47. Shen G.H., Ghazizadeh M., Kawanami O., et al. Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br J Cancer 2000, 83:196-203.
48. Dvorak H.F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002, 20:4368-4380.
49. Monk B.J., Choi D.C., Pugmire G., Burger R.A. Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer. Gynecol Oncol 2005, 96:902-905.
50. Wright J.D., Hagemann A., Rader J.S., et al. Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: a retrospective analysis. Cancer 2006, 107:83-89.
51. Cohn D.E., Valmadre S., Resnick K.E., Eaton L.A., Copeland L.J., Fowler J.M. Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer. Gynecol Oncol 2006, 102:134-139.
52. Burger R.A., Sill M.W., Monk B.J., Greer B.E., Sorosky J.I. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007, 25:5165-5171.
53. Chura J.C., Van Iseghem K., Downs L.S., Carson L.F., Judson P.L. Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Gynecol Oncol 2007, 107:326-330.
54. Simpkins F., Belinson J.L., Rose P.G. Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening. Gynecol Oncol 2007, 107:118-123.
55. Garcia A.A., Hirte H., Fleming G., et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 2008, 26:76-82.
56. Azad N.S., Posadas E.M., Kwitkowski V.E., et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 2008, 26:3709-3714.
57. Nimeiri H.S., Oza A.M., Morgan R.J., et al. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol 2008, 110:49-55.
58. Hurt J.D., Richardson D.L., Seamon L.G., et al. Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer. Gynecol Oncol 2009, 115:396-400.
59. Bidus M.A., Webb J.C., Seidman J.D., Rose G.S., Boice C.R., Elkas J.C. Sustained response to bevacizumab in refractory well-differentiated ovarian neoplasms. Gynecol Oncol 2006, 102:5-7.
60. Monk B.J., Han E., Josephs-Cowan C.A., Pugmire G., Burger R.A. Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer. Gynecol Oncol 2006, 102:140-144.
61. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
62. Numnum T.M., Rocconi R.P., Whitworth J., Barnes M.N. The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. Gynecol Oncol 2006, 102:425-428.
63. Arora N., Tewari D., Cowan C., Saffari B., Monk B.J., Burger R.A. Bevacizumab demonstrates activity in advanced refractory fallopian tube carcinoma. Int J Gynecol Cancer 2008, 18:369-372.
64. Hamilton C.A., Maxwell G.L., Chernofsky M.R., Bernstein S.A., Farley J.H., Rose G.S. Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer. Gynecol Oncol 2008, 111:530-532.
65. Kesterson J.P., Mhawech-Fauceglia P., Lele S. The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: a case report. Gynecol Oncol 2008, 111:527-529.
66. Bellati F., Napoletano C., Ruscito I., et al. Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review. Invest New Drugs 2010, 28:887-894.
67. Cannistra S.A., Matulonis U.A., Penson R.T., et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007, 25:5180-5186.
68. Han E.S., Monk B.J. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?. Gynecol Oncol 2007, 105:3-6.
69. Micha J.P., Goldstein B.H., Rettenmaier M.A., et al. A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer. Int J Gynecol Cancer 2007, 17:771-776.
70. Lee J.M., Sarosy G.A., Annunziata C.M., et al. Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity. Br J Cancer 2010, 102:495-499.
71. Chambers S.K., Clouser M.C., Baker A.F., et al. Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer. Clin Cancer Res 2010, 16:5320-5328.
72. (ID protocol number: NCT00262847). http://www.cancer.gov/.
73. (ID protocol number: NCT00483782). http://www.cancer.gov/.
74. (ID protocol number: NCT00565851). http://www.cancer.gov/.
75. (ID protocol number: NCT00434642). http://www.cancer.gov/.
76. (ID protocol number: NCT00976911). http://www.cancer.gov/.
77. Jemal A., Siegel R., Ward E., et al. Cancer Statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
78. Monk B.J, Herzog T.J. The evolution of cost-effective screening and prevention of cervical carcinoma: implications of the 2006 consensus guidelines and human papillomavirus vaccination. Am J Obstet Gynecol 2007, 197:337-339.
79. Monk B.J., Tewari K.S., Koh W.J. Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions. J Clin Oncol 2007, 25:2952-2965.
80. Long H.J., Bundy B.N., Grendys E.C., et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2005, 23:4626-4633.
81. Cooper R.A., Wilks D.P., Logue J.P., et al. High tumor angiogenesis is associated with poorer survival in carcinoma of the cervix treated with radiotherapy. Clin Cancer Res 1998, 4:2795-2800.
82. Liao S.Y., Darcy K.M., Randall L.M., et al. Prognostic relevance of carbonic anhydrase-IX in high-risk, early-stage cervical cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2010, 116:452-458.
83. Walboomers J.M., Jacobs M.V., Manos M.M., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189:12-19.
84. Toussaint-Smith E., Donner D.B., Roman A. Expression of human papillomavirus type 16 E6 and E7 oncoproteins in primary foreskin keratinocytes is sufficient to alter the expression of angiogenic factors. Oncogene 2004, 23:2988-2995.
85. López-Ocejo O., Viloria-Petit A., Bequet-Romero M., Mukhopadhyay D., Rak J., Kerbel R.S. Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner. Oncogene 2000, 19:4611-4620.
86. Wright J.D., Viviano D., Powell M.A., et al. Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer. Gynecol Oncol 2006, 103:489-493.
87. Monk B.J., Sill M.W., Burger R.A., Greer B.E., Sorosky J.I. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 2009, 27:1069-1074.
88. (ID protocol number: NCT00803062). http://www.cancer.gov/.
89. Wright J.D., Powell M.A., Rader J.S., Mutch D.G., Gibb R.K. Bevacizumab therapy in patients with recurrent uterine neoplasms. Anticancer Res 2007, 27:3525-3528.
90. Aghajanian C., Sill M.W., Darcy K., et al. A phase II evaluation of bevacizumab in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group (GOG) study - ASCO. J Clin Oncol 2009, 27:15s. [suppl; abstr 5531].
91. Kommoss S., Rochon J., Harter P., et al. Prognostic impact of additional extended surgical procedures in advanced-stage primary ovarian cancer. Ann Surg Oncol 2010, 17:279-286.
92. Zivanovic O., Eisenhauer E.L., Zhou Q., et al. The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer. Gynecol Oncol 2008, 108:287-292.
93. Armstrong D.K., Bundy B., Wenzel L., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006, 354:34-43.
94. Pujade-Lauraine E., Wagner U., Aavall-Lundqvist E., et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 2010, 28:3323-3329.
95. Bafaloukos D., Linardou H., Aravantinos G., et al. A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study. BMC Med 2010, 8:3.
96. Katsumata N., Yasuda M., Takahashi F., et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009, 374:1331-1338.
97. O'Malley D.M., Richardson D.L., Rheaume P.S., et al. Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer. Gynecol Oncol 2011, 121:269-272.
98. Markman M. Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer. Gynecol Oncol 2011, [Epub ahead of print].
99. Lau D., Guo L., Gandara D., Young L.J., Xue L. Is inhibition of cancer angiogenesis and growth by paclitaxel schedule dependent?. Anticancer Drugs 2004, 15:871-875.
100. Zitvogel L., Apetoh L., Ghiringhelli F., Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008, 8:59-73.
101. Napoletano C., Bellati F., Landi R., Pauselli S., Marchetti C., Visconti V. Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression. J Cell Mol Med 2010, 14:2748-2759.